Retinalamin®

Dosage and Administration

It is recommended to use the medicine only after a doctor's examination and upon prescription. Administration of Retinalamin® is carried out either intramuscularly or through the skin of the upper eyelid. The depth of an injection is about 1 cm.

The drug should be diluted with 1-2 ml of sodium chloride liquid (0.9%). To prevent foaming, the needle should be pointed closer to the wall of the vial.

The dose and scheme of use depend on the disease and the condition of the patient. Please refer to the official description for the detailed information on the drug administration.

Contraindications

Individual hypersensitivity; patients under 18 y.o.; pregnancy. For more information please refer to the description.

Note:

Caution should be taken when driving vehicles and operating machinery during the treatment. Parabulbar injections must be carried out by a qualified medical worker. Always follow the description and your doctor's recommendations.

Read full instruction here

Retinoprotectors are agents that protect retina from damage caused by exogenous and endogenous factors thus safeguarding eyesight from getting worse. The search for new retinoprotectors is a complex process that requires combined effort of doctors, biologists and pharmacologists. Peptide group of drugs deserve special attention. Their advantage lies in their tissue specificity, minor side effects, short duration of treatment and long-term clinical effect.
Retinalamin® is an example of a successful medical product which is based on the above mentioned principles. It is a drug with the proven cellular and molecular effectiveness.

Retinal damages vary in causes and clinical picture. They are united by the concurrent death of retinal neurons because of pathological processes with similar molecular mechanisms. The main one is excitotoxicity which is caused by an excessive activation of glutamate receptors and subsequent entry of calcium ions into a cell. Excess of calcium launches processes resulting in necrotic and apoptotic cell death. Retinalamin® is a retinoprotector that produces a direct effect on the retina. It launches mechanisms of adaptation to pathological processes and regeneration of retinal neurons improving visual functions in case of glaucoma, diabetic retinopathy and other eye disorders.

The first studies on the use of the group of drugs, which includes Retinalamin® in ophthalmology were conducted in the early 1980s at the Department of Ophthalmology of the Military Medical Academy, thus they have been in use for more than 30 years. Modern experimental studies of Retinalamin® are aimed at searching for alternative ways of administration that can facilitate the targeted drug delivery and create its depot at the optic nerve head.

The mechanism of action is determined by the metabolic activity of Retinalamin®:

  • The drug is known to activate eye tissue metabolism;
  • Normalize the functions of cellular membranes;
  • Improve intracellular synthesis of protein;
  • Regulate the processes of lipid peroxide oxidation;
  • Inhibit inflammatory processes;
  • Normalize vascular permeability;
  • Promote faster healing of injured tissues.

According to the description, Retinalamin® is indicated for:

  • Compensated primary open-angle glaucoma;
  • Diabetic retinopathy;
  • Post-traumatic and post-inflammatory central retinal dystrophy;
  • Myopia (within comprehensive treatment);
  • Dystrophic diseases of the retina.

  1. Khavinson V.Kh. et al (2002) Inductive activity of retinal peptides. https://www.ncbi.nlm.nih.gov/pubmed/12802458
  2. Khavinson V.Kh. et al (2003) Effects of peptides on proliferative activity of retinal and pigmented epithelial cells. https://www.ncbi.nlm.nih.gov/pubmed/12937684
  3. Gavrilova N.A. et al (2004) The effect of cytomedines on the hemostatic and antioxidant potential of patients in the early stage of diabetic retinopathy. https://www.ncbi.nlm.nih.gov/pubmed/15559640
  4. Khvatova A.V. et al (2005) Polypeptide bioregulators in the treatment of different-type abiotrophy of the retina. https://www.ncbi.nlm.nih.gov/pubmed/15881150
  5. Trofimova S.B. et al (2006) The effect of the bioregulating therapy on the quality of life of elderly patients with retinal pathology. https://www.ncbi.nlm.nih.gov/pubmed/16676805
  6. Aleksandrov E.I., Aleksandrova TE (2008) Treatment with the peptide bioregulator retinalamine in patients with tuberculosis of the organ of vision. https://www.ncbi.nlm.nih.gov/pubmed/18368773
  7. Kharintseva S.V. (2011) Retinoprotective therapy of diabetes macular edema in elderly patients. https://www.ncbi.nlm.nih.gov/pubmed/22184988
  8. Khavinson V.Kh. et al (2013) Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results. https://www.ncbi.nlm.nih.gov/pubmed/24003726
  9. Makashova N.V. et al (2014) Application of Retinalamin for the treatment of glaucomatous optic neuropathy. https://www.ncbi.nlm.nih.gov/pubmed/25306728
  10. Aprelev A.E. et al (2018) Results of neuroprotective therapy in primary open-angle glaucoma. https://www.ncbi.nlm.nih.gov/pubmed/30721201
  11. Egorov E.A. et al (2019) Structural and functional changes in the retina of patients with primary open-angle glaucoma and compensated intraocular pressure while undergoing retinoprotective therapy. https://www.ncbi.nlm.nih.gov/pubmed/31393444


Type: Unknown Type




CUSTOMERS WHO BOUGHT THIS PRODUCT ALSO BOUGHT